Navigation Links
ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants

e unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, future activities around ANA380/LB80380 are currently under discussion between LG Life Sciences and Anadys and there is no guarantee that the parties will be able to agree to a global development plan or next steps for the program. Furthermore, Anadys' results may be affected by risks related to its collaborative relationships with Novartis and LG Life Sciences, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, the level of effort that its collaborative partners devote to development and commercialization of its product candidates, difficulties or delays in its pre-clinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2006. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

CONTACT: Vince Reardon, Sr. Director, Investor Relations, InvestorRelations & Corporate Communications of Anadys Pharmaceuticals, Inc.,+1-858-530-3653, ; or Ki Seok Kim, GeneralManager, Investor Relations of LG Life Sciences, Ltd., +82-2-3773-0619, vreardon@anadyspharma.com




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
7. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:7/23/2014)... , July 23, 2014 UBM Medica ... – a new online community and information resource for ... manage and treat their patients with neurological disorders ... with an aging population, necessitates greater access to dedicated ...  Key statistics on neurological conditions include: , ...
(Date:7/23/2014)... , July 23, 2014 Research and ... Electrocardiograph (ECG) Market by Product, End-user & by Lead ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... segmented into three major segments, namely, holter monitor, resting, ... was valued at $3,683 million in 2013 and is ...
(Date:7/23/2014)... /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid Services ... Improvement Organization (QIN-QIO) contract to a partnership led by ... August 1, WVMI will launch Quality Insights Quality Innovation ... Pennsylvania , Delaware , ... Network will engage providers and the community in multiple, ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... obese and overweight American children and teens look in ... U.S. health officials reported Wednesday. "Being overweight or ... high blood pressure, high cholesterol and diabetes," said lead ... Centers for Disease Control and Prevention,s National Center for ...
(Date:7/23/2014)... Celebrating a decade of philanthropy in 2014, The ... of $1,070,000 in grants to 20 New Jersey non-profit ... Foundation’s 1,000th grant. , “The Horizon Foundation for New ... community-based organizations that are working to improve public health ... State,” said Robert A. Marino, Horizon Blue Cross Blue ...
(Date:7/23/2014)... Painful or itchy skin lesions could be a warning ... have multiple lesions that are suspicious looking, and those ... for non-melanoma skin cancers," study author Dr. Gil Yosipovitch, ... said in a Temple University Health System news release. ... patients who were confirmed to have skin cancer lesions ...
(Date:7/23/2014)... University in Shaanxi province, and the University of California, ... the groundwork for establishing the Sino-U.S. Joint Research Center ... was held in the city of Yingchuan, China, during ... of Agriculture and China,s Ministry of Science and Technology. ... Davis and for our World Food Center and serves ...
(Date:7/23/2014)... DC (PRWEB) July 23, 2014 ... for ATA 2015, ATA’s twentieth annual meeting and ... The meeting, expected to attract over 5,000 attendees ... will take place May 3-5, 2015, in Los ... most renowned healthcare technology professionals from researchers, clinicians, ...
Breaking Medicine News(10 mins):Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2
... previous treatments failed, trial results show , WEDNESDAY, April ... to a second-round treatment for hepatitis cures about half ... round, new research shows. , "This is the first ... standard treatment," said Dr. John G. McHutchison, associate director ...
... ... BA, RN, CIC, of Gainesville, Ga. as the 2010 recipient of the Elaine Larson ... ... Epidemiology (APIC) today announced Mary Andrus, BA, RN, CIC, of Gainesville, Ga. as the ...
... with kidney cancer, a team of researchers at Washington University ... of proteins excreted in the urine that could lead to ... research, published online in the May issue of Mayo ... in urine that appear to accurately reveal the presence of ...
... Over the past ... more than 50 percent in developing countries, bring us to the brink of polio eradication, ... ... Foundation ’s Vice President for Global Health Dr. Daniel Carucci stated, “On World Health Day ...
... ... a safe and affordable option. However, consumers need to be wary of sites ... , ... (PRWEB) April 7, 2010 -- Doctorsolve is warning consumers of the growing risk of ...
... , ... Koru Naturals, the top U.S. importer of New Zealand products, has received ... new assay and standards developed by Dr. Peter Molan. Molan Gold Standard is ... Unit, a center of excellence for the study of the health properties of ...
Cached Medicine News:Health News:New Drug Shows Promise for Curing Hepatitis C 2Health News:New Drug Shows Promise for Curing Hepatitis C 3Health News:APIC Announces Elaine Larson Lectureship Award Recipient 2Health News:APIC Announces Elaine Larson Lectureship Award Recipient 3Health News:Urine test for kidney cancer a step closer to development 2Health News:Urine test for kidney cancer a step closer to development 3Health News:United Nations Foundation Statement in Honor of World Health Day 2Health News:Real Men Don't Take Erectile Dysfunction Drugs Without a Prescription 2Health News:Real Men Don't Take Erectile Dysfunction Drugs Without a Prescription 3Health News:Koru Naturals Becomes the First U.S. Company to Import Molan Gold Standard Manuka Honey 2
... using patented, innovative technology, measures a complete ... only 5 minutes from a simple fingerstick. ... get immediate liver function results. The scope ... only advantage to healthcare providers. The physician, ...
The Strep A Rapid Test Strip is a rapid chromatographic,immunoassay for the qualitative detection of Strep A antigen,from throat swab specimens to aid in the diagnosis of Group A,Streptococcal ...
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
Medicine Products: